Skip to main content
Michael Foote, MD, Oncology, New York, NY

Michael Bonner Foote MD

Gastrointestinal Cancer


Gastrointestinal Oncologist at Memorial Sloan Kettering Cancer Center

Join to View Full Profile
  • 300 E 66th StNew York, NY 10065

  • Phone+1 646-888-5261

  • Fax+1 929-321-7326

Dr. Foote is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Summary

  • Assistant Attending

Education & Training

  • Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2019 - 2022
  • Mass General Brigham/Brigham and Women's Hospital
    Mass General Brigham/Brigham and Women's HospitalResidency, Internal Medicine, 2016 - 2019
  • Johns Hopkins University School of Medicine
    Johns Hopkins University School of MedicineClass of 2016

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2022 - Present
  • NY State Medical License
    NY State Medical License 2019 - 2026
  • NJ State Medical License
    NJ State Medical License 2022 - 2025
  • MA State Medical License
    MA State Medical License 2016 - 2019
  • Internal Medicine
    American Board of Internal Medicine Internal Medicine
  • Medical Oncology
    American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

Press Mentions

  • Adjuvant PD-1 Blockade for Mismatch Repair-Deficient Solid Cancers Directed by ctDNA Status Delivers Clinical Benefit
    Adjuvant PD-1 Blockade for Mismatch Repair-Deficient Solid Cancers Directed by ctDNA Status Delivers Clinical BenefitApril 27th, 2025
  • Neoadjuvant PD-1 Blockade in Early-Stage Mismatch Repair-Deficient Cancers Can Eliminate the Need for Surgery Regardless of Tumor Type
    Neoadjuvant PD-1 Blockade in Early-Stage Mismatch Repair-Deficient Cancers Can Eliminate the Need for Surgery Regardless of Tumor TypeApril 27th, 2025

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: